TOP TEN perturbations for 1553593_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553593_a_at
Selected probe(set): 231759_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553593_a_at (231759_at) across 6672 perturbations tested by GENEVESTIGATOR:

pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)

Relative Expression (log2-ratio):1.3836184
Number of Samples:8 / 30
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (infant)
Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-1.3191824
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

sepsis-ind. mult. organ failure study 1 / normal vastus lateralis muscle tissue

Relative Expression (log2-ratio):-1.2212238
Number of Samples:12 / 8
Experimental sepsis-ind. mult. organ failure study 1
Muscle biopsies from patients suffering from sepsis-induced multiple organ failure (MOF), treated in the intensive care unit. Biopsies were obtained from the lateral portion of the vastus lateralis muscle, 10-20 cm above the knee, using a Bergstroem biopsy needle after local anesthesia. At the time of the biopsy, all patients were circulatory stable and not suffering from severe sepsis/septic shock. At the time of biopsy all patients were considered to suffer from multiple organ failure.
Control normal vastus lateralis muscle tissue
Muscle biopsies from control patients undergoing elective surgery. Biopsies were obtained from the lateral portion of the vastus lateralis muscle, 10-20 cm above the knee, using a Bergstroem biopsy needle just after sedation.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):1.1712399
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

pediatric septic shock study 3 (toddler; subclass A) / pediatric septic shock study 3 (toddler)

Relative Expression (log2-ratio):1.1673241
Number of Samples:4 / 23
Experimental pediatric septic shock study 3 (toddler; subclass A)
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (toddler)
Whole blood obtained from toddlers (2 – 5 years) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Two children did not survive.

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):1.159792
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-1.1460037
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):-1.0973225
Number of Samples:2 / 3
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal adult kidney tissue samples.

pediatric septic shock study 3 (school-age; subclass A) / pediatric septic shock study 3 (school-age)

Relative Expression (log2-ratio):1.0918941
Number of Samples:6 / 22
Experimental pediatric septic shock study 3 (school-age; subclass A)
Whole blood samples obtained from school-age children (≥ 6 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Three children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (school-age)
Whole blood obtained from scholar age children (> 6 years of age) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. To determine survival rate, patients were followed for 28 days.

glycogen storage disease type II study 1 / normal biceps tissue

Relative Expression (log2-ratio):-1.0881987
Number of Samples:8 / 10
Experimental glycogen storage disease type II study 1
Biceps femoris muscle biopsy sample from patients with infantile onset Morbus Pompe (Pompe disease).
Control normal biceps tissue
Biceps femoris biopsy muscle samples from control subjects.